CKD strategy for Kidney Transplant Recipients and...
Transcript of CKD strategy for Kidney Transplant Recipients and...
CKD strategy for Kidney Transplant Recipients and Donors
Atsushi Aikawa !
Department of Nephrology, Toho University, Faculty of Medicine
9th International IKEA-J Symposium, Mar 1, 2014, Tokyo, Japan
9th International IKEA-J Symposium
Stage in CKD of Kidney Transplant Recipients(K/DOQI = KDIGO Guideline)
2
CKD Stage GFR (ml/min/1.73m1T ≧902T 60 ~ 893T 30 ~ 594T 15 ~ 29
5T or D <15
CKD Stage in Kidney Transplant Recipients
3
Recipients: n=115 Adult (age≧20 years) ABO Compatible Living Related Donor Kidney Transplantation in Toho University Omori Hospital (1997 ~ 2004) !eGFR (male) = 194 x Cr -1.094 x Age -0.287 eGFR (female) = 0.739 x 194 x Cr -1.094 x Age -0.287
The Rate of CKD Stage in Kidney Transplant Recipients (n = 115)
4
0%
25%
50%
75%
100%
1-yr 2-yr 3-yr 4-yr 5-yr 6-yr 7-yr
12%6%5%4%3%3%2%
4%3%
1%
14%10%9%5%7%6%5%
47%51%56%58%52%58%58%
20%25%23%28%36%29%30%
4%6%8%4%3%4%4%
Stage 1T Stage 2TStage 3T Stage 4TStage 5T Stage 5TD
5
6
Survival in Patients with CKD, PD, HD and Transplantation
CKD PD
HD Transplanted
Neovius M, Jacobson SH, Eriksson JK, et al. BMJ Open 2014;4:e004251. doi:10.1136/bmjopen-2013-004251
7
Neovius M, Jacobson SH, Eriksson JK, et al. BMJ Open 2014;4:e004251. doi:10.1136/bmjopen-2013-004251
8
Mortality Hazard Ratios (95%CI; Log Scale) v.s.
Matched General Population Comparators
CKD n=3032
PD n=724
HD n=1761
Tx n=606
Causes of Graft Failure in Kidney Transplant Recipients(n = 771; 2001~)
9Fact book 2012, Japanese Society for Transplantation
Causes of Death in Kidney Transplant Recipients(n = 356; 2001~)
10
InfectionCardiovascular DiseaseNeoplasmaStroke and Cerebral HemorrhageDigestive System DiseaseRespiratory DiseaseAccidentHematopoietic diseaseSuicideOthers
Fact book 2012, Japanese Society for Transplantation
Factors of CKD in Kidney Transplant Recipients• Immunological Factor Donor Specific HLA Antibody Chronic Antibody Mediated Rejection Chronic T Cell Medicated Rejection !
• Non Immunological Factor Metabolic Syndrome Hypertension Hyperglycemia Dyslipidemia Obesity CNI Nephrotoxicity
11
12
DSA Formation in Kidney Transplant Recipients depends on Immunosuppression
13
Immunosuppression n %antibody p valueCsA, Aza 536 18.10% Reference
CsA, MMF 533 9.80% 0.000082Tac, Aza 67 13.40% 0.34
Tac, MMF 233 12.90% 0.073
Graft Failure and Death among Kidney Transplant Patients with or without Antibody (1 Yr Follow up)
14
Pathology of Advanced CKD in Kidney Transplant Recipients (Chronic Allograft Nephropathy)
15
Interstitial fibrosis and tubular atrophy (III ; ct3, ci3)
Intimal thickening in artery (IIIb; cv3)
Arterial hyalinosis (ah3)
Metabolic Syndrome is an Independent Risk Factor of CKD
Metabolic syndrome (MS) Hypertension Hyperglycemia. Dyslipidemia Obesity !The epidemic of MS contributes to the rapid growth of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in US* and Japan**
16
* Ann Intern Med. 2004;140 (3):167–74. ** Am J Kidney Dis. 2006;48(3):383–91.
Clinical Guideline of Medical and Pediatric Complications after Kidney Transplantation
17
Post-Kidney Transplant Hypertension • BP should be less than 130/80 mmHg in kidney transplant recipients
with CKDT (grade B) • First line anti-hypersensitive drugs should be ACE-I and/or ARB
(grade B)
18
Guideline Systoric BP Diastoric BP
EBPG < 130 <80
K/DOQI < 130 <80
Clinical Guideline of CKD
Urinary Protein Neg <130 <80
Urinary Protein Pos <125 <75 Treatment of Hypertension 2009
(Japan) <130 <80
Hypertension Patient & Graft Survival
19
BP 10mmHg up RR for Graft Loss 1.12 RR for Graft Loss following Death 1.17 RR for Death 1.18
(Evidence IVa)
New Onset Diabetes Mellitus After Kidney Transplantation(NODAT)
!!!• NODAT is mainly caused by immunosuppressive agents,
such as steroid and CNI (tacrolimus and cyclosporine) !• Minimization or withdrawal of steroid and Monitoring of
blood level of CNI are critically important. !
• NODAT should be managed by a team (transplant physician, endocrinologist for DM, staff Ns, and Dietitian)
20
FBS < 130mg/dLBS 2hrs after meal < 180mg/dL
HbA1c < 6.5%
NODAT and DM
21
(Evidence IVa)
The risks of Ischemic heart disease are 2.78 times (male) and 5.4 times (female) in kidney Tx recipients with DM, compared to those without DM.
Patient survival is worse in recipients with NODAT than those without NODAT
(Evidence IVa)
Dyslipidemia• LDL-C <120mg/dl !
• LDL-C < 100mg/dl (recipients with CVD) !
• Dyslipidemia should be treated with improvement of life style and then medicine. !
• Statin is first line medicine.
22
Fluvastatin
0 1 2 3 4 5 6 7Time (years)
0
10
15
20
Cum
ulat
ive
inci
denc
e (%
)
5
Primary endpoint P = 0.036
PlaceboALERTALERT
extension
ALERT extension: Fluvastatin Significantly Reduced
the Risk of MACEFluvastatin significantly reduced the risk of MACE by 21% in patients receiving Fluvastatin throughout ALERT and the ALERT extension, compared with patients switched from placebo at the start of the extension study
Holdaas H et al: Am J Transplant 5:2929-2936, 2005
21%
Obesity• Check body weight and waist !• Obesity should be improved in terms of life style. !
• BMI < 25kg/m2
!• Gain of body weight < 5% of body weight
24
25
Graft Survival in Non-obese and Obese Transplant Recipients
26
• 56 patients had deceased donor kidney transplantation with 28 pairs.
!• one kidney from the pair into
an obese patient • the other kidney into a non-
obese patient.
27
eGFR 1 Year after Donation
28
29
Sequential Change of eGFR Following Kidney Transplantation
Clinical Courses in Living Kidney Donors Who Developed ESRD
30
ATN
ATN
Survival Rate of A Donor and General Population
31
Donor
General Population
Post-Transplantation
Survival Rate
%
No. of Donors
N Eng J Med 360;5: 459~469, 2009
32
Brigham Womens
First successful organ donor dies Posted by Elizabeth Cooney December 29, 2010 12:33 PM
Mr.Ronald Lee Herrick, who donated a kidney to his twin brother in 1954 and has died at the age of 79.